

Hall of the House of Representatives
91st General Assembly - Regular Session, 2017
Amendment Form

Subtitle of House Bill No. 1592

TO PROVIDE PARITY IN HEALTH BENEFIT PLAN COVERAGE BETWEEN ORALLY ADMINISTERED
ANTICANCER MEDICATION AND INTRAVENOUSLY ADMINISTERED ANTICANCER MEDICATION.

Amendment No. 1 to House Bill No. 1592

Amend House Bill No. 1592 as originally introduced:

Page 1, delete line 25, and substitute the following:

"SECTION 1. Effective January 1, 2018, Arkansas Code Title 23, Chapter 79, Subchapter 1, is"

AND

Page 1, delete line 32, and substitute the following:

"policy, or contract for healthcare services issued, renewed, or extended in this state and outside this state for an enrollee or certificate holder who is a resident of this state"

AND

Page 2, delete lines 16 through 18, and substitute the following:

"(b) Every health benefit plan that is issued, renewed, or extended in this state and every group health benefit plan that is issued, renewed, or extended outside this state, for an enrollee or certificate holder who is a resident of this state that provide"

AND

Page 2, delete lines 31 through 36, and substitute the following:

"(2) A healthcare insurer shall not reclassify benefits with respect to cancer treatment medications or increase a copayment, deductible, or coinsurance amount for covered cancer treatment medications that are injected or intravenously administered unless:

(A) The increase is applied generally to other medical or pharmaceutical benefits covered under the plan and is not done to circumvent subdivision (c)(1) of this section;

(B) The reclassification of benefits with respect to cancer treatment medications is done in a manner that is consistent with this section; or



(C) A healthcare insurer is applying cost-sharing increases consistent with the annual increases in the cost of health care."

AND

Page 3, delete lines 1 and 2

The Amendment was read _____
By: Representative Leding
ANS/ANS - 02-28-2017 16:32:04
ANS186

Chief Clerk